Acetaminophen Dextromethorphan Hydrobromide Saposh
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Acetaminophen Dextromethorphan Hydrobromide Saposh
- Acetaminophen / Dextromethorphan / Saposhnikovia / Tangerine Combination: Repurposing Evaluation Not Feasible
Acetaminophen / Dextromethorphan / Saposhnikovia / Tangerine Combination: Repurposing Evaluation Not Feasible
One-Sentence Summary
This product is a 4-component combination of two conventional Western drugs (acetaminophen and dextromethorphan hydrobromide) and two Traditional Chinese Medicine (TCM) herbs (saposhnikovia divaricata root and tangerine peel), most consistent in profile with a cold and upper respiratory symptom preparation. The TxGNN model was unable to generate repurposing predictions for this combination — the product holds no US market authorization, and the multi-ingredient TCM-plus-Western formulation could not be resolved to a single DrugBank node in the knowledge graph. Without prediction outputs, no evidence-based repurposing evaluation can be conducted at this stage.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no US market authorization found) |
| Predicted New Indication | None generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | Not applicable |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why the Prediction Could Not Be Generated
This combination product contains four active components:
- Acetaminophen — A first-line analgesic and antipyretic; inhibits prostaglandin synthesis centrally to relieve pain and reduce fever.
- Dextromethorphan hydrobromide — A centrally acting antitussive; acts as an NMDA receptor antagonist and sigma-1 receptor agonist to suppress the cough reflex.
- Saposhnikovia divaricata root (防風, Fangfeng) — A TCM herb traditionally indicated for wind-cold syndromes, surface pain relief, and fever; active constituents include chromones and coumarins with documented anti-inflammatory activity.
- Tangerine (陳皮/橘皮) — A TCM herb used to regulate qi, resolve phlegm, and relieve cough; the primary active constituent hesperidin has mild bronchodilatory and anti-inflammatory properties.
Taken together, this is the profile of a compound cold/flu preparation combining antipyretic, antitussive, and TCM wind-cold-clearing actions — a formulation class common in East Asian OTC markets.
However, two structural problems block TxGNN pipeline execution:
- No single DrugBank ID exists for this four-ingredient combination. The TxGNN knowledge graph operates at the level of individual drug entities; multi-component mixtures cannot be scored directly.
- No US NDA or equivalent authorization was found, so no approved indication text is available to anchor the original-indication baseline.
The TCM herbal components (saposhnikovia, tangerine peel) present an additional challenge: they typically lack standardized molecular-target profiles in Western pharmacological databases, making knowledge-graph embedding and prediction technically infeasible without custom entity modeling.
Safety Considerations
No product-level prescribing information is available for this combination as a registered entity. The individual Western medicine components carry the following established safety signals:
- Acetaminophen: Dose-dependent hepatotoxicity is the primary concern; FDA-mandated maximum daily dose is 4 g/day in adults (lower in hepatic impairment or chronic alcohol use). Concurrent use with other acetaminophen-containing products must be avoided.
- Dextromethorphan HBr: Serotonin syndrome risk with MAO inhibitors (contraindicated combination); CNS and respiratory depression at supratherapeutic doses; misuse potential at high doses (dissociative effects). Caution in patients with hepatic impairment due to CYP2D6-mediated metabolism.
For the TCM herbal components, consult the relevant pharmacopoeia (e.g., Chinese Pharmacopoeia, Taiwan Herbal Medicine Compendium) for documented herb-drug interactions and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: This combination cannot be evaluated by the TxGNN pipeline in its current multi-ingredient form — no US NDA registration exists, no DrugBank ID can be assigned to the full combination, and safety data at the product level is absent. Proceeding without these foundations would produce unreliable outputs.
To proceed, the following is needed:
- Disaggregate and evaluate individually: Submit acetaminophen and dextromethorphan as separate TxGNN candidates, where DrugBank coverage is strong and extensive clinical evidence already exists.
- Identify any registered equivalent: Confirm whether this combination is sold under a recognized brand name (domestic or international) that holds a valid NDA or equivalent approval; retrieve the product monograph to establish a formal original indication.
- Resolve TCM component mapping: Obtain pharmacokinetic and target-binding profiles for saposhnikovia divaricata root and tangerine peel from validated TCM databases (e.g., TCMSP, HerbMed) to enable knowledge-graph integration.
- Define repurposing objective: Clarify which component (or subset) is the intended repurposing candidate — broad combination repurposing is unlikely to yield actionable signals without a focused pharmacological hypothesis.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.